NVO - Novo Nordisk A/S

NYSE - NYSE Delayed price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

Currency in DKK. All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
176,954,000
176,954,000
140,800,000
126,946,000
122,021,000
Cost of revenue
28,448,000
28,448,000
23,658,000
20,932,000
20,088,000
Gross profit
148,506,000
148,506,000
117,142,000
106,014,000
101,933,000
Operating expenses
Research development
24,047,000
24,047,000
17,772,000
15,462,000
14,220,000
Selling general and administrative
50,684,000
50,684,000
41,058,000
36,886,000
35,830,000
Total operating expenses
73,697,000
73,697,000
58,498,000
51,888,000
49,450,000
Operating income or loss
74,809,000
74,809,000
58,644,000
54,126,000
52,483,000
Interest expense
378,000
378,000
2,451,000
390,000
220,000
Total other income/expenses net
-5,427,000
-5,427,000
616,000
-793,000
-3,494,000
Income before tax
69,062,000
69,062,000
59,080,000
53,130,000
48,553,000
Income tax expense
13,537,000
13,537,000
11,323,000
10,992,000
9,602,000
Income from continuing operations
55,525,000
55,525,000
47,757,000
42,138,000
38,951,000
Net income
55,525,000
55,525,000
47,757,000
42,138,000
38,951,000
Net income available to common shareholders
55,525,000
55,525,000
47,757,000
42,138,000
38,951,000
Basic EPS
-
24.51
20.79
18.05
16.41
Diluted EPS
-
24.44
20.74
18.01
16.38
Basic average shares
-
2,265,300
2,296,600
2,333,900
2,374,299
Diluted average shares
-
2,272,300
2,303,100
2,340,000
2,378,658
EBITDA
-
76,802,000
67,556,000
59,273,000
54,434,000